Enabling Precision Medicine for the Mind
That’s the promise of our approach—helping doctors objectively assess suicide risk, pain, stress, depression, and other mental health challenges, and match people to therapies that improve the quality and extend the duration of life. This results in the ability to do something unprecedented when treating pain and mental illness: proceeding with confidence. We will also collaborate with pharmaceutical companies towards their new drug development, and that of our own repurposed drug candidates.
The Process

Relief from pain and mental health suffering, in three stages.

The Hope

Now pain and mental health management can benefit from the most potent treatment of all: clarity.

Nothing is more stressful than basing crucial health decisions on guesswork. / “Is this the wrong approach?” “Is it too much?” “Not enough?” / Until now, the only approach available was dependent on a patient’s self-report and a doctor’s clinical impression. But now pain and mental health can be treated with scientific rigor. / Quantified assessments, based on biomarker research. Confident therapeutics, tailored to each individual’s unique situation. Optimism based on reality, and hope based on quantifiable results. / A relief from suffering—addressing the cause of pain and mental health problems, and the worry every solution is too imprecise. / “Wondering if you’re right” is its own kind of suffering. We’re here to end it.


Comprehensive approach. Implemented by an experienced team.

Alexander B. Niculescu, MD, PhD
Founder / Chairman / CEO
Asset 12

Dr. Niculescu developed the proprietary technologies licensed by the company. Trained as a researcher and clinician at the Scripps Research Institute and University of California at San Diego, he is currently a tenured full Professor of Psychiatry and Medical Neuroscience at Indiana University School of Medicine. He is also on the staff of the Veterans Hospital in Indianapolis, and completed an Executive MBA at IU Kelley School of Business. Dr. Niculescu is the recipient of prestigious national and international awards in the field of psychiatric genomics, and is internationally known for his work on precision medicine for mental health.

More about Dr. Niculescu.
Tien Lee, MD
Co-Founder / Board Member
Asset 12

Dr. Lee is an experienced biotech business development executive; CEO of Aardvark Therapeutics; former CSO, NantKwest.

Erik Woods, PhD
Co-Founder / Advisor
Asset 12

Dr. Woods is an experienced entrepreneur. He is co-founder and CSO of Ossium Health.

Anantha Shekhar, MD, PhD
Co-Founder / Scientific Advisor
Asset 12

Dr. Shekhar is Associate Dean for Research, IU School of Medicine; Director, Indiana Clinical and Translational Science Institute (CTSI); Leader, Precision Health Initiative. He is a Founder of Anagin, and a world-class expert in neuropsychiatric drug development and clinical trials.

Richard Hake, PhD, JD
Co-Founder / Patent Counsel
Asset 12

Dr. Hake is chief patent counsel, Metagenics. He is formerly the chief patent counsel of Kythera Biopharmaceuticals.

Stephen M. Stahl, MD, PhD, DSc
Co-Founder / CMO
Asset 12

Dr. Stahl is Professor of Psychiatry, UC San Diego, and founder of the Neuroscience Education Institute. He is chairman of Arbor Scientia, and author of Stahl’s Psychopharmacology (3rd Ed., Cambridge University Press).

Scientific Advisory Board
Don Brown, MD, MS.
Scientific Advisor / Investor
Asset 12

Dr. Brown is currently Founder and CEO, Lifeomic. He is a serial entrepreneur (Genesys/Interactive Intelligence, Software Artistry), and a world-class expert in IT and databases.

Dr. Kim Janda
Scientific Advisor
Asset 12

Dr. Janda is a world-class chemist and professor at Scripps Research.

Jerold Chun, MD, PhD
Scientific Advisor
Asset 12

Dr. Chun is a leading neuroscientist and Professor at Sanford Burnham Prebys Institute, with extensive pharma drug discovery experience.

Mike Lardon, MD
Scientific Advisor
Asset 12

Dr. Lardon is a top sports psychiatrist in San Diego that works with top athletes and CEOs.